Aripiprazole
Description
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.
Medicine classification
Medicines
Spain
Australia Austria Canada Cyprus France
Australia
Spain
Spain
Cyprus
Lithuania
Lithuania
Austria
Hong Kong
Lithuania
United States
Spain
Cyprus
United Kingdom
Hong Kong
Spain
Cyprus
Lithuania
Cyprus
Australia
Spain
Cyprus Lithuania Spain
Product monographs
2D Molecule Structure
Unique Ingredient Identifier (UNII)
82VFR53I78 - ARIPIPRAZOLE
CAS Registry Number
129722-12-9 - aripiprazole
SNOMED-CT
406784005 - Aripiprazole (substance)